The Types segment classifies POI cases into genetic, autoimmune, iatrogenic, and idiopathic categories, each with distinct epidemiological and economic implications. Genetic POI, characterized by X‑chromosome deletions, FMR1 premutations, and other monogenic defects, comprises roughly 25% of cases and commands higher diagnostic spending due to specialized sequencing. Autoimmune POI, linked to anti‑ovarian antibodies and systemic autoimmune disorders, accounts for about 20%, influencing both diagnostic and long‑term immunomodulatory therapy costs. Iatrogenic POI, resulting from chemotherapy, radiotherapy, or surgical oophorectomy, represents the largest share at 35%, because it triggers immediate intervention across multiple application areas. Idiopathic POI, where no clear etiology is identified, makes up the remaining 20% and primarily drives symptomatic treatment and monitoring expenditures. Understanding these type‑based sub‑segments is essential for accurate market sizing and for directing research funding toward the most prevalent etiologies within the Primary Ovarian Insufficiency (POI) market.